武田支付了 $200M 的预付款，以许可 Keros 的贫血药物 elritercept 治疗血癌，并有可能获得更多。 Takeda pays $200M upfront to license Keros' anemia drug, elritercept, for blood cancers, with potential for more.

Takeda已经与Keros精密治疗公司签订了一项全球许可协议, 这是一种治疗血癌中的贫血的药物, Takeda has signed a global licensing deal with Keros Therapeutics for elritercept, a drug to treat anemia in blood cancers like myelodysplastic syndromes and myelofibrosis. 武田将向 Keros 支付 2 亿美元的预付款和高达 11 亿美元的里程碑付款。 Takeda will pay Keros $200 million upfront and up to $1.1 billion in milestones. 该协议将中国排除在外,目的是通过正在进行的第二阶段试验,针对与贫血有关的蛋白质,提高精通度。 This agreement excludes China and aims to advance elritercept through ongoing Phase 2 trials, targeting proteins linked to anemia.